InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | 2026-03-19 | Berkowitz Noah | Chief Medical Officer | Sale | 6,435 | $11.10 | $71K | 202.5K | View ↗ | |
| 2026-03-06 | 2026-03-09 | Morrison Briggs | Director | Purchase | 20.0K | $13.40 | $268K | 96.0K | View ↗ | |
| 2026-02-27 | 2026-03-02 | Houston John G | Director | Sale | 35.3K | $13.21 | $466K | 1.12M | View ↗ | |
| 2026-02-23 | 2026-02-25 | Loomis David K | Chief Accounting Officer | Sale | 1,108 | $12.16 | $13K | 29.7K | View ↗ | |
| 2026-02-23 | 2026-02-25 | Cacace Angela M | Chief Scientific Officer | Sale | 3,609 | $12.16 | $44K | 147.6K | View ↗ |
No annual data found.
Catalyst Monitor: Q2 2026 Outlook Report - Trial Initiations, Completions, Top-line Results, Regulatory Filings, PDUFA Dates, and Expected Approvals
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
Protein degraders gain speed as Arvinas scores landmark approval